Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis.
Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, Scott DM, Lee WC, Cornebise M, Wortham K, Nickerson-Nutter C, Chen LL, LePage D, Spell JC, Whalley ET, Petter RC, Adams SP, Lobb RR, Pepinsky RB. Leone DR, et al. J Pharmacol Exp Ther. 2003 Jun;305(3):1150-62. doi: 10.1124/jpet.102.047332. Epub 2003 Mar 6. J Pharmacol Exp Ther. 2003. PMID: 12626659
Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
Pepinsky RB, Lee WC, Cornebise M, Gill A, Wortham K, Chen LL, Leone DR, Giza K, Dolinski BM, Perper S, Nickerson-Nutter C, Lepage D, Chakraborty A, Whalley ET, Petter RC, Adams SP, Lobb RR, Scott DM. Pepinsky RB, et al. J Pharmacol Exp Ther. 2005 Feb;312(2):742-50. doi: 10.1124/jpet.104.075648. Epub 2004 Oct 14. J Pharmacol Exp Ther. 2005. PMID: 15485895
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C, Barone D, Mohler K, Black R, Skotnicki J, Gibbons J, Feldmann M, Frost P, Larsen G, Lin LL. Zhang Y, et al. J Pharmacol Exp Ther. 2004 Apr;309(1):348-55. doi: 10.1124/jpet.103.059675. Epub 2004 Jan 12. J Pharmacol Exp Ther. 2004. PMID: 14718605
Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y, Hegen M, Xu J, Keith JC Jr, Jin G, Du X, Cummons T, Sheppard BJ, Sun L, Zhu Y, Rao VR, Wang Q, Xu W, Cowling R, Nickerson-Nutter CL, Gibbons J, Skotnicki J, Lin LL, Levin J. Zhang Y, et al. Int Immunopharmacol. 2004 Dec 20;4(14):1845-57. doi: 10.1016/j.intimp.2004.08.003. Int Immunopharmacol. 2004. PMID: 15531300
mTOR--beyond transplantation.
Young DA, Nickerson-Nutter CL. Young DA, et al. Curr Opin Pharmacol. 2005 Aug;5(4):418-23. doi: 10.1016/j.coph.2005.03.004. Curr Opin Pharmacol. 2005. PMID: 15955739 Review.
46 results